The use of UV-VIS spectroscopy for determiningthe photostability of epirubicin solutions

Authors

  • Przemysław Zalewski Department of Pharmaceutical Chemistry Author
  • Artur Firlej Department of Pharmaceutical Chemistry Author
  • Beata Medenecka Department of Pharmaceutical Chemistry Author
  • Joanna Jankowska Department of Pharmaceutical Chemistry Author
  • Jadwiga Mielcarek Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences Author
  • Irena Oszczapowicz Department of Modified Antibiotics, Institute of Biotechnology and Antibiotics, Warsaw Author

Abstract

Photostability of epirubicin – an anticancer drug – was investigated. The solution samples were exposed to UV-A and VIS radiation and the photodegradation process was monitored by using a spectrophotometric method. Epirubicin was shown to be photolabile and its photodegradation was a first-order reaction. The quantum yields of each photodegradation process were also calculated.

References

1. Aman W., Thoma K.: ICH guideline for photostability testing: aspects and directions for use. Pharmazie, 58, 877, 2003.

2. Benizri F., Bonan B., Ferrio A. L. et al.: Stability of antineoplastic agents in use for homebased intravenous chemotherapy. Pharm. World. Sci., 31, 1, 2009.

3. Dine T., Cazin J. C., Gressier B. et al.: Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags. Pharm. Weekbl. Sci., 14, 365, 1992.

4. Hortobágyj G. M.: Anthracyclines in the treatment of cancer. An overview. Drugs, 54, 1, 1997.

5. Jelińska A., Zają c M., Krzysztoń K. et al.: The use of HPLC for determining the stability 48 P. Zalewski, A. Firlej, B. Medenecka, J. Jankowska, J. Mielcarek, I. Oszczapowicz of epirubicin and the influence of ionic strength on the stabili-ty of epirubicin. Annales UMCS Sect. DDD, 19, 45, 2006.

6. Minotti G., Menna P., Salvatorelli E. et al.: Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev., 56, 185, 2004.

7. Pujol M., Munoz M., Prat J. et al.: Stability study of epirubicin in NaCl 0.9% injection.Ann. Pharmacother., 31, 992, 1997.

8. Rober t J.: Epirubicine. Clinical pharmacology and dose-effect relationship. Drugs, 45, 20, 1993.

9. Schimmel K., Richel D., van den Drink R., Guchelaar H.: Cardiotoxicity of cytotoxic drugs. Cancer Treat. Rev., 30, 181, 2004.

10. Tønnesen H. H.: Formulation and stability testing of photolabile drugs. Int. J. Pharm., 225, 1, 2001.

11. Wood M. J., Irwin W. J., Scott D.K.: Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high–performance liquid chromatography. J. Clin. Pharm. Ther., 15, 291, 1990.

Volume XXII, 4

Downloads

Published

2009-12-30

Issue

Vol. 22 No. 4 (2009): Annales UMCS, Pharmacia, Sectio DDD, Volume XXII

Section

Artykuły

License

Copyright (c) 2009 Authors

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.